KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Net Cash Flow (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Net Cash Flow for 17 consecutive years, with -$5.5 billion as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow fell 311.96% to -$5.5 billion in Q4 2025 year-over-year; TTM through Dec 2025 was -$324.0 million, a 68.7% increase, with the full-year FY2025 number at -$324.0 million, up 68.7% from a year prior.
  • Net Cash Flow was -$5.5 billion for Q4 2025 at Bristol Myers Squibb, down from $3.1 billion in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $3.9 billion in Q4 2023 to a low of -$5.5 billion in Q4 2025.
  • A 5-year average of -$236.2 million and a median of -$116.0 million in 2021 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: soared 570.92% in 2021, then crashed 2768.97% in 2022.
  • Bristol Myers Squibb's Net Cash Flow stood at $491.0 million in 2021, then skyrocketed by 159.27% to $1.3 billion in 2022, then soared by 204.24% to $3.9 billion in 2023, then plummeted by 32.84% to $2.6 billion in 2024, then plummeted by 311.96% to -$5.5 billion in 2025.
  • Per Business Quant, the three most recent readings for BMY's Net Cash Flow are -$5.5 billion (Q4 2025), $3.1 billion (Q3 2025), and $1.6 billion (Q2 2025).